Takeda PharmaceuticalTAK.NValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Richly Valued” zone.
As of Oct 16, 2026, Takeda Pharmaceutical (TAK.N) trades at a negative P/E (-374.50x, due to a recent net loss), P/B of 1.34x, P/S of 2.13x, and a dividend yield of 3.14%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 90th percentile over the trailing 10Y window (vs. 100th percentile over 3Y); P/S sits at the 87th percentile over the trailing 10Y window (vs. 100th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 32nd percentile within its industry and the 42nd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 3.70%, ranking at the 56th percentile over the trailing 20Y window.
Relative to industry peers, its P/B shows a deeper discount than it does against the broader market. Breaking down the total shareholder yield: 3.14% comes from cash dividends, with an implied ~0.56% from buybacks — a fairly balanced mix of both channels. Takeda Pharmaceutical operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NYSE: TAK · TAK
Want the full picture on whether Takeda Pharmaceutical (TAK.N) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -374.50 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 1.34 | ||||||
| P/S (TTM) | 2.13 | ||||||
| Dividend Yield | 3.14% | ||||||
| Buyback + Div Yield | 3.70% |